• Osteopore issues A$2M in redeemable convertible notes to Advance Opportunities Fund
• Funds to be used for business operations, future developments, and loan repayment
• Bridging loan with Advance Opportunities Fund I fully repaid

Osteopore Limited, an Australian-Singaporean regenerative medicine company, has announced the drawdown of the first tranche of a redeemable convertible note facility. The company entered into a subscription agreement with Advance Opportunities Fund and Advance Opportunities Fund I in December 2024 to issue up to A$20 million in convertible notes across four equal tranches of A$5 million each. The company has now confirmed that the conditions precedent for the first tranche (T1) have been fulfilled, and the subscribers have subscribed for 8 equal sub-tranches (ST01 to ST08) of the T1 Notes, totaling A$2 million. The funds raised from the issue of the Notes will be used for the company's ordinary course of business, future developments, projects, and investments, as well as to discharge and/or reduce the outstanding bridging loan agreement with Advance Opportunities Fund I. As a result, the total outstanding amount under the bridging loan has been fully repaid and satisfied.